William E Klunk

List of Publications by Year
in descending order

230 papers	47,490 citations	8181 76 h-index	1980 206 g-index
248 all docs	248 docs citations	248 times ranked	30149 citing authors

#	Article	IF	Citations
1	Biomarker clustering in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 274-284.	0.8	2
2	Direct Comparison of the Tau PET Tracers¹⁸F-Flortaucipir and¹⁸F-MK-6240 in Human Subjects. Journal of Nuclear Medicine, 2022, 63, 108-116.	5.0	39
3	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	9.0	97
4	White matter microstructure associations to amyloid burden in adults with Down syndrome. NeuroImage: Clinical, 2022, 33, 102908.	2.7	1
5	Variant-dependent heterogeneity in amyloid Î² burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study. Lancet Neurology, The, 2022, 21, 140-152.	10.2	34
6	Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12288.	2.4	2
7	Support vector machine learning and diffusion-derived structural networks predict amyloid quantity and cognition in adults with Down's syndrome. Neurobiology of Aging, 2022, 115, 112-121.	3.1	2
8	Brain health correlates of mobility-related confidence. Experimental Gerontology, 2022, 163, 111776.	2.8	1
9	11C-PiB PET can underestimate brain amyloid-Î² burden when cotton wool plaques are numerous. Brain, 2022, 145, 2161-2176.	7.6	8
10	Jointâ€label fusion brain atlases for dementia research in Down syndrome. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	2.4	1
11	Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers. JAMA Neurology, 2022, 79, 797.	9.0	17
12	Alzheimerâ€™s disease pathology in a community-based sample of older adults without dementia: The MYHAT neuroimaging study. Brain Imaging and Behavior, 2021, 15, 1355-1363.	2.1	7
13	Development of a PET radioligand selective for cerebral amyloid angiopathy. Nuclear Medicine and Biology, 2021, 92, 85-96.	0.6	6
14	Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging. Molecular Psychiatry, 2021, 26, 309-321.	7.9	47
15	Radiosynthesis, In Vitro and In Vivo Evaluation of [¹⁸F]CBD-2115 as a First-in-Class Radiotracer for Imaging 4R-Tauopathies. ACS Chemical Neuroscience, 2021, 12, 596-602.	3.5	29
16	Neurofibrillary tau depositions emerge with subthreshold cerebral beta-amyloidosis in down syndrome. NeuroImage: Clinical, 2021, 31, 102740.	2.7	9
17	PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer's disease progression in Down syndrome. NeuroImage, 2021, 228, 117728.	4.2	15
18	Robust White Matter Hyperintensity Segmentation On Unseen Domain. , 2021, 2021, 1047-1051.		5

#	Article	IF	Citations
19	Multi-Domain Learning By Meta-Learning: Taking Optimal Steps In Multi-Domain Loss Landscapes By Inner-Loop Learning. , 2021, 2021, 650-654.		3
20	An Effect of Education on Memory-Encoding Activation in Subjective Cognitive Decline. Journal of Alzheimer's Disease, 2021, 81, 1065-1078.	2.6	5
21	Characterization of point-spread function specification error on Geometric Transfer Matrix partial volume correction in [11C]PiB amyloid imaging. EJNMMI Physics, 2021, 8, 54.	2.7	0
22	Comparing amyloid-Î² plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. Acta Neuropathologica, 2021, 142, 689-706.	7.7	15
23	Peripheral inflammatory biomarkers predict the deposition and progression of amyloid-Î² in cognitively unimpaired older adults. Brain, Behavior, and Immunity, 2021, 95, 178-189.	4.1	22
24	Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study. Lancet Neurology, The, 2021, 20, 615-626.	10.2	26
25	Comparing Pathological Risk Factors for Dementia between Cognitively Normal Japanese and Americans. Brain Sciences, 2021, 11, 1180.	2.3	0
26	Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. Neurology, 2021, 97, e1823-e1834.	1.1	35
27	Physical activity and cognitive and imaging biomarkers of Alzheimer's disease in down syndrome. Neurobiology of Aging, 2021, 107, 118-127.	3.1	17
28	What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies. Journal of Nuclear Medicine, 2021, 62, 614-619.	5.0	21
29	A multi-scanner neuroimaging data harmonization using RAVEL and ComBat. NeuroImage, 2021, 245, 118703.	4.2	31
30	The effect of amyloid deposition on longitudinal resting-state functional connectivity in cognitively normal older adults. Alzheimer's Research and Therapy, 2020, 12, 7.	6.2	14
31	Improving brain age prediction models: incorporation of amyloid status in Alzheimer's disease. Neurobiology of Aging, 2020, 87, 44-48.	3.1	38
32	Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12057.	2.4	15
33	Associations between NIH Toolbox Cognition Battery and in vivo brain amyloid and tau pathology in nonâ€demented older adults. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12018.	2.4	17
34	Predicting resistance to amyloid-beta deposition and cognitive resilience in the oldest-old. Neurology, 2020, 95, e984-e994.	1.1	14
35	Hippocampal sclerosis, TDPâ€43, and the duration of the symptoms of dementia of AD patients. Annals of Clinical and Translational Neurology, 2020, 7, 1546-1556.	3.7	15
36	Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-Î² plaques in Alzheimerâ€™s disease. Acta Neuropathologica, 2020, 140, 463-476.	7.7	34

#	Article	IF	Citations
37	White matter microstructure and episodic memory in adults with down syndrome: A Tractâ€Based Spatial Statistics (TBSS) Study. Alzheimer's and Dementia, 2020, 16, e044673.	0.8	1
38	Evaluation of amyloid and tau PET quantitation methods using a 3Dâ€printed anatomically accurate brain phantom. Alzheimer's and Dementia, 2020, 16, e045455.	0.8	0
39	Amyloid accumulation in Down syndrome measured with amyloid load. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12020.	2.4	19
40	The roles of study setting, response bias, and personality in subjective memory complaints of cognitively normal older adults. International Psychogeriatrics, 2020, 33, 1-12.	1.0	3
41	A randomized controlled trial of amyloid positron emission tomography results disclosure in mild cognitive impairment. Alzheimer's and Dementia, 2020, 16, 1330-1337.	0.8	19
42	Influence of apolipoprotein-E genotype on brain amyloid load and longitudinal trajectories. Neurobiology of Aging, 2020, 94, 111-120.	3.1	15
43	Relationship of amyloid-Î²1â€“42 in blood and brain amyloid: Ginkgo Evaluation of Memory Study. Brain Communications, 2020, 2, fcz038.	3.3	10
44	Association of sleep with cognition and beta amyloid accumulation in adults with Down syndrome. Neurobiology of Aging, 2020, 93, 44-51.	3.1	24
45	Metabolic correlates of prevalent mild cognitive impairment and Alzheimer's disease in adults with Down syndrome. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12028.	2.4	12
46	Cognitive indicators of transition to preclinical and prodromal stages of Alzheimer's disease in Down syndrome. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12096.	2.4	20
47	Patterns of glucose hypometabolism in Down syndrome resemble sporadic Alzheimer's disease except for the putamen. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12138.	2.4	7
48	Statistical Methods for Processing Neuroimaging Data from Two Different Sites with a Down Syndrome Population Application. Communications in Computer and Information Science, 2020, , 367-379.	0.5	1
49	Imaging neurodegeneration in Down syndrome: brain templates for amyloid burden and tissue segmentation. Brain Imaging and Behavior, 2019, 13, 345-353.	2.1	21
50	Neuropathological correlates of amyloid PET imaging in Down syndrome. Developmental Neurobiology, 2019, 79, 750-766.	3.0	34
51	Research Use of Ecological Momentary Assessment for Adverse Event Monitoring Following Amyloid-Î² Results Disclosure. Journal of Alzheimer's Disease, 2019, 71, 1071-1079.	2.6	7
52	Investigating Gains in Neurocognition in an Intervention Trial of Exercise (IGNITE): Protocol. Contemporary Clinical Trials, 2019, 85, 105832.	1.8	26
53	Comparison of Pittsburgh compound B and florbetapir in crossâ€sectional and longitudinal studies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 180-190.	2.4	84
54	Association Between Amyloid-Î², Small-vessel Disease, and Neurodegeneration Biomarker Positivity, and Progression to Mild Cognitive Impairment in Cognitively Normal Individuals. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 1753-1760.	3.6	8

#	Article	IF	Citations
55	Leisure Activity, Brain Î²â€amyloid, and Episodic Memory in Adults with Down Syndrome. Developmental Neurobiology, 2019, 79, 738-749.	3.0	14
56	P4â€631: ALZHEIMER'S DISEASE PATHOLOGY IN A COMMUNITYâ€BASED SAMPLE OF OLDER ADULTS WITHOUT DEMENTIA: A POPULATIONâ€NEUROSCIENCE APPROACH. Alzheimer's and Dementia, 2019, 15, P1569.	0.8	0
57	Longitudinal trajectories of amyloid deposition, cortical thickness, and tau in Down syndrome: A deepâ€phenotyping case report. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 654-658.	2.4	13
58	ICâ€06â€03: SPATIAL ASSOCIATIONS OF AÎ² WITH TAU DEPOSITION IN DOWN SYNDROME. Alzheimer's and Dementia, 2019, 15, P11.	0.8	0
59	ICâ€06â€04: SLEEP, COGNITION, AND Î²â€AMYLOID IN ADULTS WITH DOWN SYNDROME. Alzheimer's and Dementia, 2019, 15, P12.	0.8	1
60	ICâ€06â€02: ASSOCIATIONS BETWEEN AÎ² AND TAU IN ADULTS WITH DOWN SYNDROME. Alzheimer's and Dementia, 2019, 15, P11.	0.8	0
61	ICâ€06â€01: ASSESSMENT OF LONGITUDINAL AMYLOID LOAD CHANGE IN DOWN SYNDROME. Alzheimer's and Dementia, 2019, 15, P10.	0.8	0
62	Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease. Molecular and Cellular Neurosciences, 2019, 97, 3-17.	2.2	82
63	Multisite study of the relationships between antemortem [¹¹C]PIBâ€PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. Alzheimer's and Dementia, 2019, 15, 205-216.	0.8	155
64	Comparison of longitudinal AÎ² in nondemented elderly and Down syndrome. Neurobiology of Aging, 2019, 73, 171-176.	3.1	13
65	Distinct cytokine profiles in human brains resilient to Alzheimer's pathology. Neurobiology of Disease, 2019, 121, 327-337.	4.4	79
66	Amyloid deposition is associated with different patterns of hippocampal connectivity in men versus women. Neurobiology of Aging, 2019, 76, 141-150.	3.1	6
67	Amyloid deposition and brain structure as long-term predictors of MCI, dementia, and mortality. Neurology, 2018, 90, e1920-e1928.	1.1	36
68	Prevalence of the apolipoprotein E Îµ4 allele in amyloid Î² positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.8	58
69	Molecular imaging: What is right and what is an illusion?. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 217-220.	2.4	11
70	Association of Cerebral Amyloid-Î² Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	11.0	133
71	Amyloid Î² Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia. JAMA Neurology, 2018, 75, 88.	9.0	33
72	P3â€440: COMPARING THE CENTILOID SCALE FOR PITTSBURGH COMPOUND B AND FLORBETAPIR IN LONGITUDINAL PET STUDIES OF SPORADIC AD. Alzheimer's and Dementia, 2018, 14, P1283.	0.8	0

#	Article	IF	Citations
73	O2â€03â€06: PREDICTING RESILIENCY AGAINST AMYLOIDâ€BETA DEPOSITION, COGNITIVE IMPAIRMENT, AND THEIR COMBINATION IN THE OLDESTâ€OLD. Alzheimer's and Dementia, 2018, 14, P619.	0.8	0
74	ICâ€Pâ€210: COMPARISON OF IN VIVO [Fâ€18]AVâ€1451 OFFâ€TARGET RETENTION IN AFRICANâ€AMERICANS AND CAUCASIANS. Alzheimer's and Dementia, 2018, 14, P173.	0.8	0
75	P1â€421: COMPARISON OF STRIATAL LONGITUDINAL CHANGES IN AMYLOID DEPOSITION IN NONâ€DEMENTED ELDERLY AND DOWN SYNDROME. Alzheimer's and Dementia, 2018, 14, P467.	0.8	0
76	ICâ€Pâ€009: COMPARING THE CENTILOID SCALE FOR PITTSBURGH COMPOUND B AND FLORBETAPIR IN LONGITUDINAL PET STUDIES OF SPORADIC AD. Alzheimer's and Dementia, 2018, 14, P19.	0.8	0
77	ICâ€Pâ€020: PREDICTING RESILIENCY AGAINST AMYLOIDâ€BETA DEPOSITION, COGNITIVE IMPAIRMENT, AND THEIR COMBINATION IN THE OLDESTâ€OLD. Alzheimer's and Dementia, 2018, 14, P25.	0.8	0
78	ICâ€Pâ€004: AMYLOID BURDEN AND CORTICAL ATROPHY IN NONâ€DEMENTED DOWN SYNDROME. Alzheimer's and Dementia, 2018, 14, P16.	0.8	0
79	P1â€437: PULSE WAVE VELOCITY IS ASSOCIATED WITH INCIDENT DEMENTIA AND AMYLOID DEPOSITION IN THE BRAINS OF ELDERLY ADULTS. Alzheimer's and Dementia, 2018, 14, P477.	0.8	0
80	P1â€429: COMPARISON OF IN VIVO [Fâ€18]AVâ€1451 OFFâ€TARGET RETENTION IN AFRICAN AMERICANS AND CAUCASIANS. Alzheimer's and Dementia, 2018, 14, P473.	0.8	0
81	P1â€445: AMYLOID BURDEN AND CORTICAL ATROPHY IN NONâ€DEMENTED DOWN SYNDROME. Alzheimer's and Dementia, 2018, 14, P484.	0.8	0
82	FTS3â€01â€01: HISTORY OF AMYLOID PET. Alzheimer's and Dementia, 2018, 14, P1004.	0.8	0
83	Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 542-555.	3.7	10
84	The use of Centiloids for applying [¹¹C]PiB classification cutoffs across regionâ€ofâ€interest delineation methods. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 332-339.	2.4	22
85	Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. NeuroImage: Clinical, 2018, 19, 406-416.	2.7	76
86	Impact of partial volume correction on the regional correspondence between in vivo [C-11]PiB PET and postmortem measures of AÎ² load. NeuroImage: Clinical, 2018, 19, 182-189.	2.7	13
87	Sleep moderates the relationship between amyloid beta and memory recall. Neurobiology of Aging, 2018, 71, 142-148.	3.1	31
88	Quantitative PET and Histology of Brain Biopsy Reveal Lack of Selective Pittsburgh Compound-B Binding to Intracerebral Amyloidoma. Journal of Alzheimer's Disease, 2018, 65, 71-77.	2.6	2
89	Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. Alzheimer's and Dementia, 2018, 14, 1565-1571.	0.8	98
90	Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented Down syndrome population. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 9, 1-9.	2.4	49

#	Article	IF	Citations
91	Pathological correlations of [Fâ€18]â€AVâ€1451 imaging in nonâ€alzheimer tauopathies. Annals of Neurology, 2017, 81, 117-128.	5.3	174
92	Small-molecule PET Tracers for Imaging Proteinopathies. Seminars in Nuclear Medicine, 2017, 47, 553-575.	4.6	91
93	Cognitive decline and brain amyloid-Î² accumulation across 3 years in adults with Down syndrome. Neurobiology of Aging, 2017, 58, 68-76.	3.1	59
94	Association of Brain Amyloid-Î² With Slow Gait in Elderly Individuals Without Dementia. JAMA Neurology, 2017, 74, 82.	9.0	66
95	Alzheimer-Like Pattern of Hypometabolism Emerges with Elevated Amyloid-Î² Burden in Down Syndrome. Journal of Alzheimer's Disease, 2017, 61, 631-644.	2.6	23
96	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimerâ€™s Disease: Results from the DIAN Study Group. PLoS ONE, 2016, 11, e0152082.	2.5	45
97	[Fâ€18]AVâ€1451 positron emission tomography retention in choroid plexus: More than â€œoffâ€targetâ€• binding. Annals of Neurology, 2016, 80, 307-308.	5.3	66
98	Cerebral Amyloid Deposition and Dual-Tasking in Cognitively Normal, Mobility Unimpaired Older Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 72, glw211.	3.6	12
99	Tenascin-C Is Associated with Cored Amyloid-Î² Plaques in Alzheimer Disease and Pathology Burdened Cognitively Normal Elderly. Journal of Neuropathology and Experimental Neurology, 2016, 75, 868-876.	1.7	31
100	Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2016, 52, 17-24.	2.6	35
101	Post-mortem histopathology underlying Î²-amyloid PET imaging following flutemetamol F 18 injection. Acta Neuropathologica Communications, 2016, 4, 130.	5.2	76
102	The effects of normal aging on amyloidâ€Î² deposition in nondemented adults with Down syndrome as imaged by carbon 11â€“labeled Pittsburgh compound B. Alzheimer's and Dementia, 2016, 12, 380-390.	0.8	65
103	Comparison of qualitative and quantitative imaging characteristics of [11 C]PiB and [18 F]flutemetamol in normal control and Alzheimer's subjects. NeuroImage: Clinical, 2015, 9, 592-598.	2.7	48
104	A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2015, 7, 50.	6.2	10
105	Validating novel tau positron emission tomography tracer <scp>[Fâ€18]â€AVâ€1451 (T807)</scp> on postmortem brain tissue. Annals of Neurology, 2015, 78, 787-800.	5.3	535
106	Amyloid-Î² Imaging in Older Adults Presenting to a Memory Clinic with Subjective Cognitive Decline: A Pilot Study. Journal of Alzheimer's Disease, 2015, 48, S151-S159.	2.6	80
107	More evidence for association of a rare TREM2 mutation (R47H) with Alzheimer's disease risk. Neurobiology of Aging, 2015, 36, 2443.e21-2443.e26.	3.1	39
108	The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. Alzheimer's and Dementia, 2015, 11, 1.	0.8	603

#	Article	IF	Citations
109	Endogenous murine AÎ² increases amyloid deposition in APP23 but not in APPPS1 transgenic mice. Neurobiology of Aging, 2015, 36, 2241-2247.	3.1	9
110	Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study. Lancet Neurology, The, 2015, 14, 804-813.	10.2	91
111	Where is hippocampal activity in the cascade of Alzheimerâ€™s disease biomarkers?. Brain, 2015, 138, 831-833.	7.6	8
112	Incidental Cerebral Microbleeds and Cerebral Blood Flow in Elderly Individuals. JAMA Neurology, 2015, 72, 1021.	9.0	71
113	Subjective Cognitive Complaints, Personality and Brain Amyloid-beta inÂCognitively Normal Older Adults. American Journal of Geriatric Psychiatry, 2015, 23, 985-993.	1.2	112
114	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	7.4	1,166
115	Prevalence of Amyloid PET Positivity in Dementia Syndromes. JAMA - Journal of the American Medical Association, 2015, 313, 1939.	7.4	501
116	Relative ¹¹C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session ¹⁵O-Water and ¹¹C-PiB PET. Journal of Nuclear Medicine, 2015, 56, 1199-1205.	5.0	62
117	Amyloid-Î² ¹¹ C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology, 2015, 85, 692-700.	1.1	136
118	Hyperphosphorylated Tau is Elevated in Alzheimer's Disease with Psychosis. Journal of Alzheimer's Disease, 2014, 39, 759-773.	2.6	46
119	Amyloid Imaging With Carbon 11â€“Labeled Pittsburgh Compound B for Traumatic Brain Injury. JAMA Neurology, 2014, 71, 23.	9.0	132
120	Arterial Stiffness and Î²-Amyloid Progression in Nondemented Elderly Adults. JAMA Neurology, 2014, 71, 562.	9.0	152
121	Early detection of Alzheimer's disease using PiB and FDG PET. Neurobiology of Disease, 2014, 72, 117-122.	4.4	164
122	Markers of cholesterol transport are associated with amyloid deposition in the brain. Neurobiology of Aging, 2014, 35, 802-807.	3.1	62
123	Amyloid, neurodegeneration, and small vessel disease as predictors of dementia in the oldest-old. Neurology, 2014, 83, 1804-1811.	1.1	46
124	Cognitive functioning in relation to brain amyloid-Î² in healthy adults with Down syndrome. Brain, 2014, 137, 2556-2563.	7.6	87
125	Amyloid burden and neural function in people at risk for Alzheimer's Disease. Neurobiology of Aging, 2014, 35, 576-584.	3.1	166
126	Development and Screening of Contrast Agents for In Vivo Imaging of Parkinsonâ€™s Disease. Molecular Imaging and Biology, 2013, 15, 585-595.	2.6	21

#	Article	IF	Citations
127	Amyloid and neurodegeneration. Neurology, 2013, 81, 1728-1729.	1.1	6
128	Cognitive aging in persons with minimal amyloid-Î² and white matter hyperintensities. Neuropsychologia, 2013, 51, 2202-2209.	1.6	31
129	Disclosure of amyloid imaging results to research participants: Has the time come?. Alzheimer's and Dementia, 2013, 9, 741.	0.8	37
130	Classification of amyloid-positivity in controls: Comparison of visual read and quantitative approaches. NeuroImage, 2013, 71, 207-215.	4.2	77
131	Imaging Tau Deposits InÂVivo: Progress in Viewing More of The Proteopathy Picture. Neuron, 2013, 79, 1035-1037.	8.1	13
132	Cognitive trajectories associated with Î²-amyloid deposition in the oldest-old without dementia. Neurology, 2013, 80, 1378-1384.	1.1	77
133	Pulse wave velocity is associated with Î²-amyloid deposition in the brains of very elderly adults. Neurology, 2013, 81, 1711-1718.	1.1	156
134	Positron emission tomography radioligands for in vivo imaging of AÎ² plaques. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 89-95.	1.0	53
135	In vivo assessment of amyloidâ€Î² deposition in nondemented very elderly subjects. Annals of Neurology, 2013, 73, 751-761.	5.3	89
136	Anomalous PiB enhancement in the Superior Sagittal and Transverse Venous Sinuses. Alzheimer Disease and Associated Disorders, 2012, 26, 186-190.	1.3	1
137	Using Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta. Advances in Pharmacology, 2012, 64, 27-81.	2.0	78
138	Developing an international network for Alzheimerâ€™s research: the Dominantly Inherited Alzheimer Network. Clinical Investigation, 2012, 2, 975-984.	0.0	180
139	Brain Imaging in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006213-a006213.	6.2	502
140	Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. New England Journal of Medicine, 2012, 367, 795-804.	27.0	3,005
141	Correspondence between in vivo 11C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques. Acta Neuropathologica, 2012, 124, 823-831.	7.7	98
142	Amyloid imaging in dementias with atypical presentation. , 2012, 8, 389-398.		46
143	Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B. Alzheimer's and Dementia, 2012, 8, 496-501.	0.8	116
144	Î²-Amyloid 42/40 ratio and kalirin expression in Alzheimer disease with psychosis. Neurobiology of Aging, 2012, 33, 2807-2816.	3.1	40

#	Article	IF	Citations
145	Development of Positron Emission Tomography Î²-Amyloid Plaque Imaging Agents. Seminars in Nuclear Medicine, 2012, 42, 423-432.	4.6	155
146	Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab. Archives of Neurology, 2012, 69, 198.	4.5	349
147	Positron emission tomography imaging of amyloid-beta plaque deposition: a decade of translation. Journal of Translational Medicine, 2012, 10, .	4.4	1
148	AÎ² Imaging: feasible, pertinent, and vital to progress in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 209-219.	6.4	55
149	Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study. Acta Neuropathologica, 2012, 123, 433-447.	7.7	78
150	Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET. NeuroImage, 2011, 55, 933-941.	4.2	47
151	Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends in Neurosciences, 2011, 34, 430-442.	8.6	309
152	Lack of association between 11C-PiB and longitudinal brain atrophy in non-demented older individuals. Neurobiology of Aging, 2011, 32, 2123-2130.	3.1	39
153	Amyloid imaging as a biomarker for cerebral Î²-amyloidosis and risk prediction for Alzheimer dementia. Neurobiology of Aging, 2011, 32, S20-S36.	3.1	120
154	The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Agingâ€Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 263-269.	0.8	12,681
155	Longitudinal assessment of AÎ² and cognition in aging and Alzheimer disease. Annals of Neurology, 2011, 69, 181-192.	5.3	730
156	In Vivo Fibrillar Î²-Amyloid Detected Using [11C]PiB Positron Emission Tomography and Neuropathologic Assessment in Older Adults. Archives of Neurology, 2011, 68, 232-40.	4.5	102
157	The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. , 2011, 7, 263.		1
158	11C-PiB PET assessment of change in fibrillar amyloid-Î² load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurology, The, 2010, 9, 363-372.	10.2	674
159	Progression of Cerebral Amyloid Load Is Associated with the Apolipoprotein E Îµ4 Genotype in Alzheimer's Disease. Biological Psychiatry, 2010, 68, 879-884.	1.3	103
160	Consideration of Optimal Time Window for Pittsburgh Compound B PET Summed Uptake Measurements. Journal of Nuclear Medicine, 2009, 50, 348-355.	5.0	108
161	Basal Cerebral Metabolism May Modulate the Cognitive Effects of AÎ² in Mild Cognitive Impairment: An Example of Brain Reserve. Journal of Neuroscience, 2009, 29, 14770-14778.	3.6	217
162	Fibrillar amyloid-Î² burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 6820-6825.	7.1	700

#	Article	IF	Citations
163	Absence of Pittsburgh Compound B Detection of Cerebral Amyloid Î² in a Patient With Clinical, Cognitive, and Cerebrospinal Fluid Markers of Alzheimer Disease. Archives of Neurology, 2009, 66, 1557-62.	4.5	188
164	Amyloid imaging in mild cognitive impairment subtypes. Annals of Neurology, 2009, 65, 557-568.	5.3	309
165	Update on amyloid imaging: From healthy aging to Alzheimerâ€™s disease. Current Neurology and Neuroscience Reports, 2009, 9, 345-352.	4.2	55
166	PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET. Neurobiology of Aging, 2009, 30, 1217-1226.	3.1	118
167	Clinical severity of Alzheimer's disease is associated with PIB uptake in PET. Neurobiology of Aging, 2009, 30, 1902-1909.	3.1	89
168	Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid. Biological Psychiatry, 2009, 65, 927-934.	1.3	256
169	Amyloid Imaging with PET in Alzheimerâ€™s Disease, Mild Cognitive Impairment, and Clinically Unimpaired Subjects. , 2009, , 119-147.		9
170	14 Amyloid Imaging and (What is â€œNormalâ€?) Aging. , 2009, , 191-244.		2
171	Measuring Target Effect of Proposed Disease-Modifying Therapies in Alzheimer's Disease. Neurotherapeutics, 2008, 5, 381-390.	4.4	23
172	Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B. Journal of Neuroscience Methods, 2008, 172, 277-282.	2.5	75
173	Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimerâ€™s disease. NeuroImage, 2008, 39, 619-633.	4.2	201
174	Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly. Archives of Neurology, 2008, 65, 1509.	4.5	923
175	Biopsy Support for the Validity of Pittsburgh Compound B Positron Emission Tomography With a Twist. Archives of Neurology, 2008, 65, 1281-3.	4.5	11
176	Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain, 2008, 131, 1630-1645.	7.6	837
177	Longitudinal Cerebral Blood Flow and Amyloid Deposition: An Emerging Pattern?. Journal of Nuclear Medicine, 2008, 49, 1465-1471.	5.0	59
178	11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain, 2008, 131, 665-680.	7.6	819
179	Imaging Alzheimer Pathology in Late-Life Depression With PET and Pittsburgh Compound-B. Alzheimer Disease and Associated Disorders, 2008, 22, 261-268.	1.3	119
180	Whatever Happened to Pittsburgh Compound-A?. Alzheimer Disease and Associated Disorders, 2008, 22, 198-203.	1.3	9

#	Article	IF	Citations
181	The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation. Current Opinion in Neurology, 2008, 21, 683-687.	3.6	85
182	Â-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain, 2007, 130, 2837-2844.	7.6	739
183	Amyloid Deposition Begins in the Striatum of Presenilin-1 Mutation Carriers from Two Unrelated Pedigrees. Journal of Neuroscience, 2007, 27, 6174-6184.	3.6	358
184	Molecular Imaging With Pittsburgh Compound B Confirmed at Autopsy. Archives of Neurology, 2007, 64, 431.	4.5	326
185	Impact of amyloid imaging on drug development in Alzheimer's disease. Nuclear Medicine and Biology, 2007, 34, 809-822.	0.6	115
186	Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease. NeuroImage, 2007, 36, 298-312.	4.2	96
187	Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Annals of Neurology, 2007, 62, 229-234.	5.3	465
188	Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. NeuroImage, 2006, 33, 94-102.	4.2	116
189	Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid AÎ²₄₂ in humans. Annals of Neurology, 2006, 59, 512-519.	5.3	1,190
190	Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain, 2006, 129, 2805-2807.	7.6	54
191	Xâ€34 Labeling of Abnormal Protein Aggregates During the Progression of Alzheimer's Disease. Methods in Enzymology, 2006, 412, 123-144.	1.0	52
192	Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, 1528-1547.	4.3	622
193	In Vivo Optical Imaging of Amyloid Aggregates in Brain: Design of Fluorescent Markers. Angewandte Chemie - International Edition, 2005, 44, 5452-5456.	13.8	303
194	Imaging Technology for Neurodegenerative Diseases. Archives of Neurology, 2005, 62, 196.	4.5	69
195	Role of biomarkers in studies of presymptomatic Alzheimer's disease. , 2005, 1, 145-151.		23
196	Commentary on â€œDiagnosis of Alzheimer's disease: Two decades of progress.â€•Diagnosis of Alzheimer's disease: Walking a well-paved path. , 2005, 1, 99-100.		0
197	Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory. Journal of Neuroscience, 2005, 25, 7709-7717.	3.6	1,839
198	Binding of the Positron Emission Tomography Tracer Pittsburgh Compound-B Reflects the Amount of Amyloid-Î² in Alzheimer's Disease Brain But Not in Transgenic Mouse Brain. Journal of Neuroscience, 2005, 25, 10598-10606.	3.6	357

#	Article	IF	Citations
199	Simplified quantification of PIB amyloid imaging PET studies. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S589-S589.	4.3	3
200	Anti-AÎ² antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. Journal of Clinical Investigation, 2005, 115, 428-433.	8.2	161
201	Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. Journal of Nuclear Medicine, 2005, 46, 1959-72.	5.0	398
202	Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compoundâ€B. Annals of Neurology, 2004, 55, 306-319.	5.3	3,777
203	Targeting Prion Amyloid Deposits In Vivo. Journal of Neuropathology and Experimental Neurology, 2004, 63, 775-784.	1.7	32
204	Synthesis and Evaluation of ¹¹C-Labeled 6-Substituted 2-Arylbenzothiazoles as Amyloid Imaging Agents. Journal of Medicinal Chemistry, 2003, 46, 2740-2754.	6.4	921
205	Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. Neuroimaging Clinics of North America, 2003, 13, 781-789.	1.0	74
206	Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-Â ligand in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 12462-12467.	7.1	253
207	The Binding of 2-(4â€²-Methylaminophenyl)Benzothiazole to Postmortem Brain Homogenates Is Dominated by the Amyloid Component. Journal of Neuroscience, 2003, 23, 2086-2092.	3.6	269
208	Imaging AÎ² Plaques in Living Transgenic Mice with Multiphoton Microscopy and Methoxy-X04, a Systemically Administered Congo Red Derivative. Journal of Neuropathology and Experimental Neurology, 2002, 61, 797-805.	1.7	366
209	Apolipoprotein E and Alpha-1-Antichymotrypsin Genotypes Do Not Predict Time to Psychosis in Alzheimer's Disease. Journal of Geriatric Psychiatry and Neurology, 2002, 15, 24-30.	2.3	20
210	Blood and CSF biomarkers for AD revisited: whatâ€™s new, whatâ€™s good, and is this where we should be looking?. Neurobiology of Aging, 2002, 23, 517-519.	3.1	9
211	Psychosis in Alzheimer disease: postmortem magnetic resonance spectroscopy evidence of excess neuronal and membrane phospholipid pathology. Neurobiology of Aging, 2002, 23, 547-553.	3.1	60
212	Synthesis and11C-labelling of (E,E)-1-(3?,4?-dihydroxystyryl)-4-(3?-methoxy-4?-hydroxystyryl) benzene for PET imaging of amyloid deposits?. Journal of Labelled Compounds and Radiopharmaceuticals, 2002, 45, 647-664.	1.0	22
213	A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 295-298.	2.2	343
214	Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34. Neurobiology of Aging, 2001, 22, 217-226.	3.1	147
215	Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sciences, 2001, 69, 1471-1484.	4.3	408
216	The 5-HTTPR Polymorphism Confers Liability to a Combined Phenotype of Psychotic and Aggressive Behavior in Alzheimer Disease. International Psychogeriatrics, 2001, 13, 401-409.	1.0	103

#	Article	IF	Citations
217	Psychotic Symptoms in Alzheimer's Disease Are Not Associated With More Severe Neuropathologic Features. International Psychogeriatrics, 2000, 12, 547-558.	1.0	56
218	X-34, A Fluorescent Derivative of Congo Red: A Novel Histochemical Stain for Alzheimer's Disease Pathology. Journal of Histochemistry and Cytochemistry, 2000, 48, 1223-1232.	2.5	253
219	Quantifying Amyloid Î²-Peptide (AÎ²) Aggregation Using the Congo Red-AÎ² (CRâ€“AÎ²) Spectrophotometric Assay. Analytical Biochemistry, 1999, 266, 66-76.	2.4	283
220	Effect of phosphomonoesters, phosphodiesters, and phosphocreatine on glutamate uptake by synaptic vesicles. Molecular and Chemical Neuropathology, 1997, 32, 89-99.	1.0	5
221	Aggregation of Î²â€Amyloid Peptide Is Promoted by Membrane Phospholipid Metabolites Elevated in Alzheimer's Disease Brain. Journal of Neurochemistry, 1997, 69, 266-272.	3.9	25
222	Magnetic Resonance Spectroscopy of Neural Tissue. Methods in Neurosciences, 1996, , 178-208.	0.5	1
223	Structural determinants of activity at the GABAB receptor. Molecular and Chemical Neuropathology, 1995, 26, 15-30.	1.0	9
224	Development of small molecule probes for the Beta-amyloid protein of Alzheimer's Disease. Neurobiology of Aging, 1994, 15, 691-698.	3.1	171
225	Alterations of cerebral metabolism in probable Alzheimer's disease: A preliminary study. Neurobiology of Aging, 1994, 15, 117-132.	3.1	171
226	Analysis of magnetic resonance spectra by mole percent: Comparison to absolute units. Neurobiology of Aging, 1994, 15, 133-140.	3.1	76
227	NMR Identification of the Formic Acidâ€Modified Residue in Alzheimer's Amyloid Protein. Journal of Neurochemistry, 1994, 62, 349-354.	3.9	15
228	L-Phosphoserine, a Metabolite Elevated in Alzheimer's Disease, Interacts with Specific L-Glutamate Receptor Subtypes. Journal of Neurochemistry, 1991, 56, 1997-2003.	3.9	30
229	Alzheimer's ?-Amyloid Protein Is Covalently Modified when Dissolved in Formic Acid. Journal of Neurochemistry, 1990, 54, 2050-2056.	3.9	26
230	CSF Biomarkers in Down Syndrome and Autosomal Dominant Alzheimer Disease. SSRN Electronic Journal, 0, , .	0.4	0